A phase II study of OSI-774 (Tarceva) [erlotinib] in combination with capecitabine in previously treated patients with metastatic pancreatic cancer.

Next Previous
Trial Profile

A phase II study of OSI-774 (Tarceva) [erlotinib] in combination with capecitabine in previously treated patients with metastatic pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Capecitabine; Erlotinib
  • Indications Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Nov 2009 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Actual patient number (32) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top